hotspot -WSS

hotspot

author：hotspot 2025-10-02 23:47:58 - browse：14

A black and white cutout photo of Feng Zhang on the left of a black and white cutout photo of Alex Aravanis. Both photos are placed on top of yellow geometric shapes and a gradient dark blue background. — Researcher Feng Zhang, left, and Alex Aravanis, the CEO of Moonwalk. Illustration: Christine Kao/STAT; Photo: Katherine Taylor for STAT and Business Wire

A new startup co-founded by CRISPR innovator Feng Zhang, a former executive at Grail and Illumina, and others has raised $57 million to develop a defanged form of gene editing that doesn’t cut the DNA strand.

Moonwalk Therapeutics launched Thursday with funding from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, Khosla Ventures, GV, and YK Bioventures. It plans to use that money to develop treatments for a variety of diseases, including chronic and aging-related conditions, using what’s called epigenetic editing.

Most of the gene editing technologies being used today slice or nick the DNA strand and make permanent changes to the biological building blocks of genes. Moonwalk, however, plans to alter the activity of genes by focusing on chemical changes. The company is targeting the surrounding chemicals that influence how genes act. This can be done through chemical processes methylation, which turns genes on, or demethylation, which turns genes off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Latest bird flu infection made farmworker sicker than earlier cases

WSS

Lab trade group sues FDA to halt regulation of lab

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Study on Amgen’s bispecific immunotherapy produces positive data

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

How AI can help patients find reliable information about doctors

focus

hotspot

focus

Sports medicine is finally prioritizing gender equality

Insmed lung disease drug hits target in key Phase 3 trial

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Summit: How researchers deal with rejection

Heart attack and stroke risk calculators need revising

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Moonlake's readout produced a cash windfall. Risks remain

STAT Readout Newsletter: Biotech news today

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Average age of first period drops to 11.9 years, study shows

entertainment

Childbirth

STAT Readout: Friday, Oct. 20 biotech updates

Dark money group runs ads on China biotech bill

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Readout LOUD podcast: Live from the 2023 STAT Summit

AI used to predict Covid

hotspot

leisure time

focus

hotspot